Scientists from Shanghai Zelgen Pharmatech Co. Ltd., Suzhou Zelgen Biosciences Co. Ltd. and Zejing Pharmaceutical (Zhejiang) Co. Ltd. have presented GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.